每周序贯抗生素预防用于神经源性膀胱患者复发性尿路感染:一项随机对照试验
本研究为随机开放标签优效性试验,纳入45例因脊髓损伤致神经源性膀胱并反复发生尿路感染的患者,比较每周口服环丙抗生素预防(WOCA,即每周交替使用2种抗生素)与无预防(对照)6个月的效果。结果显示WOCA组症状性需抗生素治疗的尿路感染中位发生率低于对照组,且无发热性尿路感染发生,耐受性良好,未观察到细菌耐药出现。
要点
- WOCA可降低脊髓损伤后神经源性膀胱患者的复发性症状性尿路感染发生率。
- WOCA组无发热性尿路感染,对照组有9例(45.0%)。
- WOCA耐受性良好,未观察到尿路、肠道及鼻腔菌群耐药 emergence。
核心结论
- WOCA预防在脊髓损伤致神经源性膀胱患者中可有效且耐受性良好地预防复发性尿路感染。
- 研究未观察到消化和鼻腔微生物培养中出现抗生素耐药。
研究设计与样本
- 随机(1:1)、开放标签、优效性对照试验,比较WOCA预防与无预防(对照)6个月。
- 纳入45例因脊髓损伤致神经源性膀胱、使用清洁间歇自行导尿且患有复发性尿路感染的患者。
- WOCA组23例,对照组22例。
主要发现
- 症状性需抗生素治疗的尿路感染中位发生率(IQR)WOCA组为1.0(0.5-2.5),对照组为2.5(1.2-4.0)(P = .0241)。
- WOCA组无发热性尿路感染记录,对照组为9例(45.0%)(P < .001)。
- 额外抗生素治疗中位数(IQR)WOCA组为0.0(0.0-2.0),对照组为3.0(2.0-5.0)(P = .004)。
- 仅报告少数不良事件。
- 未观察到细菌耐药出现的影响。
临床怎么用
- 对于脊髓损伤后神经源性膀胱且反复发生尿路感染的患者,可考虑每周口服环丙抗生素预防以降低症状性尿路感染和发热性尿路感染风险。
- 使用WOCA预防时需监测不良事件,尽管本研究中未观察到耐药出现,仍需关注耐药风险。
局限性
- 样本量较小(共45例),可能影响结果的普遍性。
- 开放标签设计可能引入偏倚。
- 研究仅随访6个月,长期疗效和耐药风险需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent urinary tract infections (R-UTIs) are the main cause of morbidity and hospitalizations in subjects with neurogenic bladder (NB) due to spinal cord injury (SCI). We evaluated the efficacy of weekly oral cyclic antibiotic (WOCA) prophylaxis (ie, the alternate weekly administration of 2 antibiotics) in preventing R-UTIs. METHODS: Randomized (1:1), open-label, superiority-controlled trial compared WOCA prophylaxis to no prophylaxis (control) for 6 months in patients with NB due to SCI, using clean intermittent self-catheterization, and suffering from R-UTIs. Primary outcome was incidence of symptomatic antibiotic-treated UTIs. Secondary outcomes were number of febrile UTIs, number of hospitalizations, WOCA tolerance, antibiotic consumption, number of negative urine cultures, and emergence of bacterial resistance in urinary, intestinal, and nasal microbiota. RESULTS: Forty-five patients were either allocated to the WOCA group (n = 23) or the control group (n = 22). Median (IQR) incidence of symptomatic antibiotic-treated UTIs was 1.0 (0.5-2.5) in the WOCA group versus 2.5 (1.2-4.0) (P = .0241) in the control group. No febrile UTIs were recorded in the WOCA group versus 9 (45.0%) (P < .001) in the control group. The median number of additional antibiotic treatment was 0.0 (IQR, 0.0-2.0) versus 3.0 (2.0-5.0) (P = .004) in the WOCA and control groups, respectively. Only few adverse events were reported. No impact on emergence of bacterial resistance was observed. CONCLUSIONS: WOCA is efficient and well tolerated in preventing R-UTIs in SCI patients. In our study, we did not observe any emergence of antibiotic resistance in digestive and nasal microbiological cultures. CLINICAL TRIALS REGISTRATION: NCT01388413.
引用
- Dinh A, Hallouin-Bernard MC, Davido B, et al. Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections Among Patients With Neurogenic Bladder: A Randomized Controlled Trial. Clin Infect Dis. 2020. PMID: 31867616. doi:10.1093/cid/ciz1207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。